Ricken, R, Ulrich, S, Schlattmann, P, et al. Tranylcypromine in mind (part II): review of clinical pharmacology and meta-analysis of controlled studies in depression. Eur Neuropsychopharmacol. 2017; 27(8): 714–731.
Amsterdam, JD, Shults, J. MAOI efficacy and safety in advanced stage treatment-resistant depression–a retrospective study. J Affect Disord. 2005; 89(1–3): 183–188.
Shulman, KI, Fischer, HD, Herrmann, N, et al. Current prescription patterns and safety profile of irreversible monoamine oxidase inhibitors: a population-based cohort study of older adults. J Clin Psychiatry. 2009; 70(12): 1681–1686.
Birkenhager, TK, van den Broek, WW, Mulder, PG, et al. Efficacy and tolerability of tranylcypromine versus phenelzine: a double-blind study in antidepressant-refractory depressed inpatients. J Clin Psychiatry. 2004; 65(11): 1505–1510.
Adli, M, Pilhatsch, M, Bauer, M, et al. Safety of high-intensity treatment with the irreversible monoamine oxidase inhibitor tranylcypromine in patients with treatment-resistant depression. Pharmacopsychiatry. 2008; 41(6): 252–257.
Razani, J, White, KL, White, J, et al. The safety and efficacy of combined amitriptyline and tranylcypromine antidepressant treatment. A controlled trial. Arch Gen Psychiatry. 1983; 40(6): 657–661.
Shulman, KI, Herrmann, N, Walker, SE. Current place of monoamine oxidase inhibitors in the treatment of depression. CNS Drugs. 2013; 27(10): 789–797.
Gillman, PK. A reassesment of the safety profile of monoamine oxidase inhibitors: elucidating tired old tyramine myths. J Neural Transm (Vienna). 2018; 125(11): 1707–1717.
Gillman, PK. “Much ado about nothing”: monoamine oxidase inhibitors, drug interactions, and dietary tyramine. CNS Spectr. 2017; 22(5): 390.
Stahl, SM. Stahl’s Essential Psychopharmacology: The Prescribers Guide. 6th ed. New York, NY: Cambridge University Press; 2017.
Sackett, DL, Rosenberg, WM, Gray, JA, et al. Evidence based medicine: What it is and what it isn’t. BMJ. 1996; 312(7023): 71–72.
Greenhalgh, T, Snow, R, Ryan, S, et al. Six ‘biases’ against patients and carers in evidence-based medicine. BMC Medicine. 2015; 13: 200.